Identification of prognostic factors for γδT cell immunotherapy in patients with solid tumor
| Autor: | Tomoharu Miyashita, Sachiko Okada, Keiko Naitoh, Eri Oguma, Takashi Kamigaki, Kaori Makita, Hiroshi Ibe, Katsuro Tomita, Kosei Yasumoto, Shigenori Goto, Rishu Takimoto, Eishiro Mizukoshi |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male 0301 basic medicine Oncology Cancer Research medicine.medical_specialty T-Lymphocytes medicine.medical_treatment Immunology Kaplan-Meier Estimate Immunotherapy Adoptive Flow cytometry 03 medical and health sciences 0302 clinical medicine Neoplasms Internal medicine Humans Immunology and Allergy Medicine Cytotoxicity Genetics (clinical) Aged Retrospective Studies Aged 80 and over Transplantation Chemotherapy medicine.diagnostic_test business.industry Proportional hazards model Hazard ratio Receptors Antigen T-Cell gamma-delta Cell Biology Immunotherapy Middle Aged Flow Cytometry Prognosis medicine.disease Radiation therapy Treatment Outcome 030104 developmental biology 030220 oncology & carcinogenesis Female business Progressive disease |
| Zdroj: | Cytotherapy. 22:329-336 |
| ISSN: | 1465-3249 |
| Popis: | Background aims Activated γδT cells have been shown to exhibit cytotoxicity against tumor cells. However, the efficacy of γδT cell immunotherapy for a large number of patients with solid tumors remains unclear. In this study, we examined the efficacy of γδT cell immunotherapy using in vitro-activated γδT lymphocytes in combination with standard therapies in terms of the survival of patients with solid tumors, and determined prognostic factor for γδT cell immunotherapy. Methods 131 patients enrolled in this study received γδT cell immunotherapy with or without standard therapies. Their overall survival was analyzed by the Kaplan-Meier with log-rank test and Cox regression methods. Immunological analysis was performed by flow cytometry (FCM) before and after six cycles of γδT cell immunotherapy. Results Multivariable analysis revealed that patients who showed stable disease (SD) and partial response (PR) to γδT cell immunotherapy showed better prognosis than those with a progressive disease (PD) (P = 0.0269, hazard ratio [HR], 0.410, 95% confidence interval [CI], 0.190–0.901). Furthermore, when immunological parameters were examined by FCM, the high Vγ9/γδT ratio (i.e., the high purity of the Vγ9 cells within the adoptively transferred γδT cells) before treatment was found to be a good prognostic factor for γδT cell immunotherapy (P = 0.0142, HR, 0.328, 95% CI, 0.125–0.801). No serious adverse events were reported during γδT cell immunotherapy. Conclusion Thus, γδT cell immunotherapy might extend the survival of patients with solid tumors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect